These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 8622265)

  • 1. [A phase 3 clinical trial of 123I-iomazenil, a new central-type benzodiazepine receptor imaging agent (Part 3)--Report on clinical usefulness in epilepsy].
    Torizuka K; Uemura K; Toru M; Shinohara Y; Nishimura T; Yonekura Y; Nakagawara J; Matsuda H; Sakai F; Matsuda K; Fukuyama H; Morimoto K
    Kaku Igaku; 1996 Mar; 33(3):319-28. PubMed ID: 8622265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Phase 2 clinical study of 123I-iomazenil in various cerebral diseases: part 2--clinical evaluation of central-type benzodiazepine receptor imaging with 123I-iomazenil SPECT].
    Torizuka K; Uemura K; Thoru M; Yonekura Y; Nakagawara J; Fukuyama H; Matsuda K; Morimoto K
    Kaku Igaku; 1996 Feb; 33(2):191-205. PubMed ID: 8721108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A phase 3 clinical trial of 123I-iomazenil, a new central-type benzodiazepine receptor imaging agent (Part 2)--Report on clinical usefulness in diagnosis of degenerative neurological diseases and mental disorders].
    Torizuka K; Uemura K; Toru M; Shinohara Y; Nishimura T; Yonekura Y; Nakagawara J; Matsuda H; Sakai F; Matsuda K; Fukuyama H; Morimoto K
    Kaku Igaku; 1996 Mar; 33(3):303-18. PubMed ID: 8622264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A phase 3 clinical trial of 123I-iomazenil, a new central-type benzodiazepine receptor imaging agent (Part 1)--report on clinical usefulness in diagnosis of various brain diseases].
    Torizuka K; Uemura K; Toru M; Shinohara Y; Nishimura T; Yonekura Y; Nakagawara J; Matsuda H; Sakai F; Matsuda K; Fukuyama H; Morimoto K
    Kaku Igaku; 1996 Mar; 33(3):293-301. PubMed ID: 8622263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A phase 3 clinical trial of 123I-iomazenil, a new central-type benzodiazepine receptor imaging agent (Part 4)--Report on clinical usefulness in diagnosis of cerebrovascular diseases].
    Torizuka K; Uemura K; Toru M; Shinohara Y; Nishimura T; Yonekura Y; Nakagawara J; Matsuda H; Sakai F; Matsuda K; Fukuyama H; Morimoto K
    Kaku Igaku; 1996 Mar; 33(3):329-44. PubMed ID: 8622266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Assessment of cerebral benzodiazepine receptor distribution in epilepsy by 123I-iomazenil-SPECT].
    Uchiyama M; Sue H; Fukumitsu N; Mori Y; Kawakami K
    Nihon Igaku Hoshasen Gakkai Zasshi; 1997 Jan; 57(1):47-51. PubMed ID: 9038063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Presurgical identification of epileptic foci with iodine-123 iomazenil SPET: comparison with brain perfusion SPET and FDG PET.
    Tanaka F; Yonekura Y; Ikeda A; Terada K; Mikuni N; Nishizawa S; Ishizu K; Okazawa H; Hattori N; Shibasaki H; Konishi J; Onishi Y
    Eur J Nucl Med; 1997 Jan; 24(1):27-34. PubMed ID: 9044873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Usefulness of 123I-iomazenil SPECT in pediatric patients with neurological disease].
    Kuki I; Kawawaki H; Okazaki S; Inoue T; Nukui M; Tomiwa K; Amou K; Togawa M; Shiomi M
    No To Hattatsu; 2012 Jan; 44(1):5-12. PubMed ID: 22352023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Central-type benzodiazepine receptors and epileptogenesis: basic mechanisms and clinical validity.
    Morimoto K; Tamagami H; Matsuda K
    Epilepsia; 2005; 46 Suppl 5():184-8. PubMed ID: 15987275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Phase 2 clinical study of 123I-iomazenil in various cerebral diseases: part 1--examination of injection dose and clinical indications].
    Torizuka K; Uemura K; Tohru M; Yonekura Y; Nakagawara J; Fukuyama H; Matsuda K; Morimoto K
    Kaku Igaku; 1996 Feb; 33(2):179-90. PubMed ID: 8721107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Phase 1 clinical study of 123I-iomazenil: a new probe to evaluate central-type benzodiazepine receptor with SPECT].
    Yonekura Y; Nishizawa S; Tanaka F; Ishizu K; Okazawa H; Fujita T; Konishi J; Torizuka K
    Kaku Igaku; 1995 Jan; 32(1):87-97. PubMed ID: 7897872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of benzodiazepine receptors using iodine-123-labeled iomazenil single-photon emission computed tomography in patients with ischemic cerebrovascular disease. A comparison with PET study.
    Dong Y; Fukuyama H; Nabatame H; Yamauchi H; Shibasaki H; Yonekura Y
    Stroke; 1997 Sep; 28(9):1776-82. PubMed ID: 9303025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations of benzodiazepine receptor binding potential in anxiety and somatoform disorders measured by 123I-iomazenil SPECT.
    Tokunaga M; Ida I; Higuchi T; Mikuni M
    Radiat Med; 1997; 15(3):163-9. PubMed ID: 9278373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Benzodiazepine receptor and cerebral blood flow in early Alzheimer's disease--SPECT study using 123I-iomazenil and 123I-IMP].
    Kitamura S; Koshi Y; Komiyama T; Sakayori O; Komaba Y; Ohyama M; Mishina M; Tsuganesawa T; Terashi A
    Kaku Igaku; 1996 Jan; 33(1):49-56. PubMed ID: 8819714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usefulness of 123I-iomazenil single-photon emission computed tomography in discriminating between mesial and lateral temporal lobe epilepsy in patients in whom magnetic resonance imaging demonstrates normal findings.
    Umeoka S; Matsuda K; Baba K; Usui N; Tottori T; Terada K; Usui K; Nakamura F; Inoue Y; Fujiwara T; Mihara T
    J Neurosurg; 2007 Aug; 107(2):352-63. PubMed ID: 17695390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual Isotope SPECT Study With Epilepsy Patients Using Semiconductor SPECT System.
    Shiga T; Suzuki A; Sakurai K; Kurita T; Takeuchi W; Toyonaga T; Hirata K; Kobashi K; Katoh C; Kubo N; Tamaki N
    Clin Nucl Med; 2017 Sep; 42(9):663-668. PubMed ID: 28682842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benzodiazepine receptors in chronic cerebrovascular disease: comparison with blood flow and metabolism.
    Sasaki M; Ichiya Y; Kuwabara Y; Yoshida T; Fukumura T; Masuda K
    J Nucl Med; 1997 Nov; 38(11):1693-8. PubMed ID: 9374335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative estimation of I-123-Iomazenil receptor binding in temporal lobe epilepsies using two SPECT acquisitions--comparison with the regional cerebral blood flow and a compartment model.
    Venz S; Hierholzer J; Cordes M; Straub HB; Keske U; Meencke HJ; Eichstädt H; Felix R
    Nuklearmedizin; 1998 Mar; 37(2):49-56. PubMed ID: 9547750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Compartment analysis of 123I-iomazenil brain on early and delayed SPECT].
    Yanagimoto S; Ono S; Sone T; Morita K; Nagai K; Otsuka N; Mimura H; Tomomitsu T; Fukunaga M; Muranaka A; Itaya M; Kitayama A
    Kaku Igaku; 1997 Jun; 34(6):371-7. PubMed ID: 9267122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of outcome by EC/IC bypass with 123I-iomazenil brain SPECT.
    Makino K; Kamiyama H; Takamura H; Gotoh S; Kobayashi N
    Ann Nucl Med; 1999 Aug; 13(4):261-4. PubMed ID: 10510883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.